Emcure Pharmaceuticals IPO: Shark Tank India judge Namita Thapar likely to earn ₹127 cr from the IPO, check details

Shark Tank India judge Namita Thapar will earn over ₹127.87 crore through the upcoming Emcure Pharmaceuticals IPO. The initial public offer is set to open subscription on Wednesday, July 3. Namita, one of the promoters of the pharma company, will sell over 12.68 lakh shares through the offer for sale (OFS) component in the ₹1,952-crore Emcure Pharmaceuticals IPO.

As per Emcure Pharmaceuticals RHP, the stake sale will make her rake in more than ₹127 crore at the upper price band of ₹1,008 of the IPO.

The Shark Tank India fame investor acquired these shares at a weighted average price of ₹3.44 per piece, which means she will earn a return of nearly 294 times on her investments.

As per the pre-issue stake-holding structure of Emcure Pharmaceuticals Ltd, Namita Thapar owned around 63 lakh shares, or 3.5% stake, of the company.

To know more and invest in Emcure Pharmaceuticals IPO, CLICK HERE

Emcure Pharma IPO is a book-building issue valued at ₹1,952.03 crore, offered at a price band in the range of ₹960 to ₹1008 per share. The public offer constitutes a fresh issue of 79 lakh shares aimed at raising ₹800 crores and (OFS) of 1.14 crore shares worth ₹1,152.03 crores.

Apart from Namita Thapar, the pharma firm's full-time director, other promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, and Samit Satish Mehta will also offload their stakes through the OFS portion of the public issue.

Satish Ramanlal Mehta, the Managing director and the largest shareholder of Emcure Pharmaceuticals, controlling 75,816,748 shares, or 41.85% stake, in the company pre-issue, will sell up to 4.2 lakh equity shares via OFS.

Promoter Samit Satish Mehta, who owns a 7.48% stake in Emcure ahead of the issue, will sell 10,000 equity shares while Sunil Rajanikant Mehta will offload as much as 40,000 equity shares.

Emcure Pharma IPO dates

Emcure Pharma IPO subscription will be live between July 3, Wednesday and July 5, Friday. Retail investors can submit their bids for a minimum of 1 lot size of 14 shares, aggregating to an investment of ₹14,112 at the upper end of the price band.

While the IPO share allotment status is expected to be finalised on July 8, Emcure Pharma IPO listing date has been tentatively fixed as July 10. Shares of Emcure Pharma will be listed on the NSE and BSE.

Emcure Pharma Ltd has appointed Axis Capital Limited, JP Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited as the book-running lead managers for the IPO. Link Intime India Private Ltd is the public issue's registrar.

Emcure Pharmaceuticals Limited, incorporated in 1981, is engaged in developing, manufacturing, and marketing pharmaceutical products. Operating 13 manufacturing facilities in India, the company has a market presence in more than 70 countries. Emcure Pharma claims to be the third largest pharmaceutical player in the gynaecology and human immunodeficiency virus (HIV) antiviral therapeutic segments in India.

To know more about IPOs listing, schedule and upcoming IPOs, click here